Why the study?
Acute pulmonary embolism is a life-threatening emergency where early reperfusion improves outcomes in high-risk conditions, but optimal use of catheter-directed therapies requires further clarification.
Do interventional reperfusion strategies improve clinical outcomes and risk-benefit ratio compared to systemic thrombolysis in patients with acute pulmonary embolism?
Do interventional reperfusion strategies improve clinical outcomes and risk-benefit ratio compared to systemic thrombolysis in patients with acute pulmonary embolism?
Catheter-directed therapies offer a promising alternative to systemic thrombolysis for acute pulmonary embolism, though further trials are needed to define optimal patient selection.
Answers are grounded in this paper and cite their sources.
May support catheter-based therapies in select acute PE; leaves open optimal selection and superiority vs systemic thrombolysis pending RCTs.
Acute pulmonary embolism (APE) is a common, potentially life-threatening cardiovascular emergency, and represents the third leading cause of cardiovascular mortality after myocardial infarction and stroke. Risk stratification is important to guide the management of APE, as an early reperfusion strategy is associated with improved clinical outcomes in specific high-risk conditions. Pulmonary artery reperfusion is commonly achieved by systemic intravenous administration of thrombolytic drugs, but catheter-directed thrombolysis (CDThr) and interventional techniques of catheter-based embolectomy provide novel therapeutic approaches with an improved risk-benefit ratio. Future trials will help to determine when to use these different devices in massive or sub-massive APE, and which patient population is likely to benefit from interventional treatment.
No takes yet. Share an insight, caveat, or question.
Draxler et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: